Edesa Biotech Standort der Zentrale
Was ist das Standort der Zentrale von Edesa Biotech?
Standort der Zentrale von Edesa Biotech, Inc. ist Canada
Was ist die Definition von Standort der Zentrale?
Standort der Zentrale
Foreign companies can be traded on US stock markets and vice-versa. Obligation of foreign companies traded on US exchanges might slightly differ from obligations of domestic companies.
Was macht Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.